News Summary: Roche 3Q drug sales rise 7 percent

SALES JUMP: Powered by demand for its cancer drugs, Swiss drugmaker Roche on Tuesday reported a 7 percent increase in sales of its pharmaceutical products for the first nine months of 2012.

THE DETAILS: The world's biggest producer of cancer-fighting drugs said its pharmaceutical division's sales over the three quarters rose to 26.2 billion Swiss francs ($28.08 billion), from 24.4 billion francs in the same time period last year.

CANCER DRUGS: The company, based in Basel, Switzerland, had solid growth in its top three cancer drugs _ MabThera/Rituxan, Herceptin and Avastin, which it said accounted for 52 percent of the division's sales.